Back to Search Start Over

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors

Authors :
Qurratulain Yousuf
Leonard D. Goldstein
Ivan Pedrosa
Rong Lu
Xin Luo
Xinlei Wang
Raquibul Hannan
He Zhang
James Brugarolas
Mingyi Chen
Christina Stevens
Jason J. Luke
Wenbin Guo
Allison Joyce
Tao Wang
Yi Feng Gu
Eric Stawiski
Jose R. Torrealba
Somasekar Seshagiri
Oreoluwa Onabolu
Zhiqun Xie
Alexander Filatenkov
Ze Zhang
Bijay S. Jaiswal
Zora Modrusan
Payal Kapur
Min S. Kim
Tiffani McKenzie
Jingxuan He
Danni Luo
Steffen Durinck
Source :
Cancer Discovery. 8:1142-1155
Publication Year :
2018
Publisher :
American Association for Cancer Research (AACR), 2018.

Abstract

By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found that 65% of previously defined immune signature genes are not abundantly expressed in renal cell carcinoma (RCC) and identified 610 novel immune/stromal transcripts. Using eTME, genomics, pathology, and medical record data involving >1,000 patients, we established an inflamed pan-RCC subtype (IS) enriched for regulatory T cells, natural killer cells, TH1 cells, neutrophils, macrophages, B cells, and CD8+ T cells. IS is enriched for aggressive RCCs, including BAP1-deficient clear-cell and type 2 papillary tumors. The IS subtype correlated with systemic manifestations of inflammation such as thrombocytosis and anemia, which are enigmatic predictors of poor prognosis. Furthermore, IS was a strong predictor of poor survival. Our analyses suggest that tumor cells drive the stromal immune response. These data provide a missing link between tumor cells, the TME, and systemic factors. Significance: We undertook a novel empirical approach to dissect the renal cell carcinoma TME by leveraging tumorgrafts. The dissection and downstream analyses uncovered missing links between tumor cells, the TME, systemic manifestations of inflammation, and poor prognosis. Cancer Discov; 8(9); 1142–55. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1047

Details

ISSN :
21598290 and 21598274
Volume :
8
Database :
OpenAIRE
Journal :
Cancer Discovery
Accession number :
edsair.doi.dedup.....30727601a9619585b3e0d4d3b8fb9c1a
Full Text :
https://doi.org/10.1158/2159-8290.cd-17-1246